Claudio Bassi
University of Verona
704 Papers
4.3K Citations
Claudio Bassi is an academic researcher from University of Verona. The author has contributed to research in topics: Medicine & Pancreatic cancer. The author has an hindex of 99, co-authored 637 publications. Previous affiliations of Claudio Bassi include Heidelberg University & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
Residual pancreatic function after pancreaticoduodenectomy is better preserved with pancreaticojejunostomy than pancreaticogastrostomy: A long-term analysis.
Luigi Benini,Armando Gabbrielli,Chiara Cristofori,Antonio Amodio,Giovanni Butturini,Nicolò Cardobi,Carlo Sozzi,Luca Frulloni,Roberto Pozzi Mucelli,Stefano Francesco Crinò,Claudio Bassi,Giovanni Marchegiani,Stefano Andrianello,Giuseppe Malleo,Roberto Salvia +14 more
TL;DR: Compared to PJ, PG is associated with a more severely impaired exocrine function long-term, but they result similar endocrine function and quality of life in patients with a long life expectancy.
17
Antibacterial and mezlocillin-enhancing activity of pure human pancreatic fluid.
Claudio Bassi,Roberta Fontana,Sergio Vesentini,Giorgio Cavallini,Marchiori L,Massimo Falconi,Stefano Corrà,Paolo Pederzoli +7 more
TL;DR: Pure human pancreatic fluid showed properties similar to those observed in the dog against E. coli and produced a 75 % reduction in mezlocillin MICs against this organism, which might make the commonly used doses sufficient for prophylactic purposes.
17
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Laura Maggino,Giuseppe Malleo,Stefano Crippa,Giulio Belfiori,S. Nobile,Giulia Gasparini,Gabriella Lionetto,Claudio Luchini,Paola Mattiolo,Marco Schiavo-Lena,Claudio Doglioni,Aldo Scarpa,Claudio Bassi,Massimo Falconi,Roberto Salvia +14 more
TL;DR: In this article , the authors investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectably pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy.
Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
Andrea Mambrini,Claudio Bassi,Paola Pacetti,Tito Torri,Calogero Iacono,Michela Ballardini,M. Orlandi,Stefano Guadagni,Giammaria Fiorentini,Maurizio Cantore +9 more
TL;DR: Pain reduction, stage of disease, and number of administered cycles are independent prognostic factors of overall survival in a multivariate analysis of patients with advanced pancreatic cancer receiving FLEC regimen intra-arterially.
17